Payment overview · 2025
General Payments
$3,393.45
207 reported records · 21 companies
Healthcare provider profile · identity verified
Kenneth John Adessa, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Hospice and Palliative Medicine · PARSIPPANY, NJ · NPI 1750348520
Verified facts
What the public records show
CMS Open Payments records show Kenneth John Adessa, MD received $3,393.45 in general payments during 2025 across 207 reported records.
Novo Nordisk Inc accounted for 14.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 34 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Jardiance, Kerendia, Mounjaro, Otezla, Ozempic, Rybelsus.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 506 claims for Eliquis by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 212 claims for Xarelto by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 506 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $483.62 | 14.2% | 35 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $471.09 | 13.9% | 31 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $346.91 | 10.2% | 25 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $248.67 | 7.3% | 16 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $247.53 | 7.3% | 12 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $237.74 | 7.0% | 10 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $211.21 | 6.2% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $195.20 | 5.8% | 14 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $194.75 | 5.7% | 12 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $176.29 | 5.2% | 10 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $151.44 | 4.5% | 10 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $113.02 | 3.3% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.79 | 2.7% | 5 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $48.51 | 1.4% | 3 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $48.23 | 1.4% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $32.84 | 1.0% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $29.43 | 0.9% | 2 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $18.62 | 0.6% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.83 | 0.5% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.88 | 0.4% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $13.85 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,393.45 | 207 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $471.09 | 31 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $346.91 | 25 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $341.92 | 25 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $250.76 | 17 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $247.53 | 12 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $237.74 | 10 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $233.47 | 15 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $233.47 | 15 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $211.21 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $195.20 | 14 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $195.20 | 14 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $176.47 | 11 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $151.44 | 10 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $128.29 | 7 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $126.36 | 9 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.02 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $96.94 | 6 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $92.79 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.46 | 3 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $48.51 | 3 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $48.23 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.00 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $43.43 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $32.84 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $29.43 | 2 | 2025 |
Source payment records
|
|||||
| INVEGA SUSTENNA Normalized: invega sustenna |
Drug | Janssen Pharmaceuticals, Inc | $18.62 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $18.28 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $16.83 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $14.88 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 55 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 171 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 110 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 128 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 89 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
65 | 12 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
171 | 20 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 21 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
506 | 49 |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
212 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
128 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
102 | 13 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
89 | 16 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
506 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1138 | 171 |
| Amlodipine Besylate | Amlodipine Besylate | 739 | 121 |
| Eliquis | Apixaban | 506 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 440 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 420 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 417 | 58 |
| Mirtazapine | Mirtazapine | 393 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 379 | 41 |
| Gabapentin | Gabapentin | 369 | 41 |
| Sertraline Hcl | Sertraline Hcl | 355 | 37 |
| Losartan Potassium | Losartan Potassium | 353 | 62 |
| Metformin Hcl | Metformin Hcl | 344 | 60 |
| Furosemide | Furosemide | 327 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 265 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 259 | 39 |
| Lisinopril | Lisinopril | 236 | 35 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 233 | suppressed |
| Xarelto | Rivaroxaban | 212 | 12 |
| Divalproex Sodium | Divalproex Sodium | 211 | 16 |
| Alprazolam | Alprazolam | 192 | 51 |
| Donepezil Hcl | Donepezil Hcl | 191 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 178 | 16 |
| Farxiga | Dapagliflozin Propanediol | 171 | 20 |
| Carvedilol | Carvedilol | 164 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 155 | 20 |
| Valsartan | Valsartan | 150 | 12 |
| Finasteride | Finasteride | 147 | 15 |
| Memantine Hcl | Memantine Hcl | 144 | 15 |
| Trazodone Hcl | Trazodone Hcl | 141 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 133 | suppressed |
| Omeprazole | Omeprazole | 130 | 27 |
| Mounjaro | Tirzepatide | 128 | 17 |
| Meclizine Hcl | Meclizine Hcl | 124 | 15 |
| Risperidone | Risperidone | 119 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 116 | 21 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 115 | 39 |
| Divalproex Sodium Er | Divalproex Sodium | 112 | suppressed |
| Famotidine | Famotidine | 110 | 23 |
| Jardiance | Empagliflozin | 110 | 21 |
| Myrbetriq | Mirabegron | 109 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 109 | 31 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 18 |
| Januvia | Sitagliptin Phosphate | 106 | 17 |
| Trulicity | Dulaglutide | 102 | 13 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 95 | 11 |
| Clonazepam | Clonazepam | 94 | 14 |
| Levetiracetam | Levetiracetam | 93 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 92 | 11 |
| Montelukast Sodium | Montelukast Sodium | 89 | suppressed |
| Ozempic | Semaglutide | 89 | 16 |
| Potassium Chloride | Potassium Chloride | 88 | 17 |
| Azithromycin | Azithromycin | 86 | 65 |
| Atenolol | Atenolol | 78 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 77 | 19 |
| Amoxicillin | Amoxicillin | 76 | 64 |
| Baclofen | Baclofen | 76 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 23 |
| Latanoprost | Latanoprost | 73 | 12 |
| Simvastatin | Simvastatin | 72 | 16 |
| Lorazepam | Lorazepam | 71 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 12 |
| Spironolactone | Spironolactone | 66 | 13 |
| Synthroid | Levothyroxine Sodium | 65 | 12 |
| Allopurinol | Allopurinol | 64 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 63 | 14 |
| Lurasidone Hcl | Lurasidone Hcl | 61 | suppressed |
| Dalfampridine Er | Dalfampridine | 59 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 15 |
| Memantine Hcl Er | Memantine Hcl | 58 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | suppressed |
| Meloxicam | Meloxicam | 57 | 16 |
| Prednisone | Prednisone | 57 | 14 |
| Torsemide | Torsemide | 56 | 11 |
| Amantadine | Amantadine Hcl | 55 | suppressed |
| Entresto | Sacubitril/Valsartan | 55 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 55 | 18 |
| Repaglinide | Repaglinide | 55 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 53 | 12 |
| Diazepam | Diazepam | 51 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 50 | suppressed |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 48 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 47 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 47 | 15 |
| Glipizide | Glipizide | 46 | suppressed |
| Nystatin | Nystatin | 45 | 17 |
| Buspirone Hcl | Buspirone Hcl | 43 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 42 | suppressed |
| Digoxin | Digoxin | 41 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Olanzapine | Olanzapine | 40 | suppressed |
| Temazepam | Temazepam | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 39 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 38 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 37 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 37 | suppressed |
| Aripiprazole | Aripiprazole | 35 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 35 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 34 | 15 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Nystop | Nystatin | 34 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 28 |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | suppressed |
| Lactulose | Lactulose | 33 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 33 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 33 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 33 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 31 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 30 | suppressed |
| Clonidine | Clonidine | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 30 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Gemtesa | Vibegron | 28 | suppressed |
| Nifedipine Er | Nifedipine | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 27 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Ondansetron Odt | Ondansetron | 27 | suppressed |
| Tradjenta | Linagliptin | 27 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 27 | suppressed |
| Creon | Lipase/Protease/Amylase | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Ursodiol | Ursodiol | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Topiramate | Topiramate | 25 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Alogliptin | Alogliptin Benzoate | 23 | suppressed |
| Cephalexin | Cephalexin | 23 | 16 |
| Colchicine | Colchicine | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | 12 |
| Letrozole | Letrozole | 23 | suppressed |
| Lidocaine | Lidocaine | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 22 | suppressed |
| Fluconazole | Fluconazole | 22 | 13 |
| Mupirocin | Mupirocin | 22 | 14 |
| Methimazole | Methimazole | 21 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 21 | suppressed |
| Insulin Lispro | Insulin Lispro | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Primidone | Primidone | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Belsomra | Suvorexant | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Constulose | Lactulose | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Levofloxacin | Levofloxacin | 19 | 17 |
| Methenamine Hippurate | Methenamine Hippurate | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Kerendia | Finerenone | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Nyamyc | Nystatin | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 17 | suppressed |
| Metolazone | Metolazone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Calcitriol | Calcitriol | 16 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 15 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 14 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 14 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 11 |
| Norvasc | Amlodipine Besylate | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 11 |
| Praluent Pen | Alirocumab | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Acetylcysteine | Acetylcysteine | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 13 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Mirabegron Er | Mirabegron | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Procrit | Epoetin Alfa | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Benicar | Olmesartan Medoxomil | 12 | suppressed |
| Ciclopirox | Ciclopirox | 12 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Klayesta | Nystatin | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Repatha Pushtronex | Evolocumab | 11 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 11 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,393.45 · 207 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AUSTEDO XR, BREZTRI, COBENFY, COMIRNATY, CONTRAVE, Cologuard Collection Kit, ENTRESTO, FARXIGA, IBSRELA, INVEGA SUSTENNA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, RELISTOR, REPATHA, REXULTI, Rybelsus, Symbravo, UBRELVY, WELLBUTRIN, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE | 18 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error